Biohaven Ltd. Stock price

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on advancing a pipeline of therapies for diseases with little or no treatment options, leveraging its drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for Obsessive-Compulsive Disorder (OCD) and Spinocerebellar Ataxia (SCA), myostatin inhibition for neuromuscular diseases, and brain-penetrant Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for immune-mediated brain disorders. Its portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and extracellular target degrader platform technology (MoDE) with potential application in neurological disorders, cancer, and autoimmune diseases.